Date: Aug 20, 2013 Author: press release Source: Company Data (
click here to go to the source)
Riparian Pharmaceuticals, Inc. is pleased to announce that it has been awarded a Phase I Small Business Technology Transfer grant from the National Heart, Lung and Blood Institute of the National Institutes of Health.
Atherosclerosis, the disease process underlying heart attacks, strokes and peripheral artery disease, is a leading cause of death worldwide. In addition to the well-known importance of hypertension, blood cholesterol levels and diabetes, chronic inflammation is a potent risk factor that significantly contributes to the progression of atherosclerosis. This grant will fund research establishing a new approach for the treatment of atherosclerosis by targeting hemodynamics-induced inflammation in the blood vessel wall.
"We appreciate the support and enthusiasm from the National Heart, Lung and Blood Institute and are excited to break ground on an innovative therapeutic strategy to mitigate the inflammation burden in cardiovascular disease" said Dr. William Adams, Riparian Chief Scientific Officer and co-founder.
